Commercial Regeneron Q1 2026 net income falls 10% to $727m Pharmaceutical Business ReviewOn a non-GAAP basis, net income rose 12% to $1.04bn from $928m.Read full story pharminent April 30, 2026 (Last updated: April 30, 2026) Pharmaceutical Business Review On a non-GAAP basis, net income rose 12% to $1.04bn from $928m. Read full story Post navigation Previous: Ray Therapeutics receives EMA PRIME status for gene therapyNext: Norgine gets first EU approval for WHIM syndrome therapy Related Stories Commercial Novo drops ‘Nordisk’ moniker, turns bull toward future in corporate rebrand pharminent September 14, 2026 Commercial Lilly’s $23B Q2 soars over expectations but Foundayo lags Novo’s rival oral GLP-1 pharminent August 5, 2026 Commercial Leqembi sales grow again after subcutaneous approvals pharminent July 29, 2026